Skip to main content

Table 2 Median survival data (months) of metastatic angiosarcomas

From: Survival predictors of metastatic angiosarcomas: a surveillance, epidemiology, and end results program population-based retrospective study

Variable OS CSS
Estimate ± SE 95%CI Estimate ± SE 95%CI
Age at diagnosis (years)
 ≤ 60 5.0 ± 0.9 3.323–6.677 5.0 ± 0.9 3.228–6.772
 > 60 2.0 ± 0.4 1.168–2.832 2.0 ± 0.5 1.005–2.995
Gender
 Female 4.0 ± 0.7 2.575–5.425 4.0 ± 1.0 2.100–5.900
 Male 3.0 ± 0.6 1.795–4.205 3.0 ± 0.6 1.845–4.155
Race
 White 3.0 ± 0.5 2.063–3.937 3.0 ± 0.5 1.972–4.028
 Black 4.0 ± 1.7 0.757–7.243 4.0 ± 1.4 1.309–6.691
 Other 6.0 ± 4.2 0.000–14.305 6.0 ± 2.6 0.842–11.158
Year of diagnosis
 2010–2012 4.0 ± 1.0 2.068–5.932 3.0 ± 0.9 1.280–4.720
 2013–2014 4.0 ± 0.8 2.403–5.597 3.0 ± 0.9 1.272–4.728
 2015–2016 3.0 ± 0.6 1.844–4.156 3.0 ± 1.0 1.124–4.876
Grade
 I + II N/A N/A 3.0 ± 0.6 1.863–4.137
 III 4.0 ± 1.0 2.137–5.863 4.0 ± 1.5 0.986–7.014
 IV 4.0 ± 0.7 2.534–5.466 4.0 ± 0.7 2.588–5.412
NO. of metastatic sites
 1 3.0 ± 0.6 1.789–4.211 4.0 ± 0.9 2.162–5.838
 ≥ 2 3.0 ± 0.7 1.589–4.411 3.0 ± 0.7 1.629–4.371
Size (cm)
 ≤ 10 6.0 ± 1.1 3.887–8.113 9.0 ± 1.9 5.337–12.663
 > 10 2.0 ± 0.7 0.701–3.299 3.0 ± 0.6 1.840–4.160
Treatment
 Chemotherapy
  Yes 8.0 ± 1.0 6.083–9.917 8.0 ± 1.3 5.444–10.556
  No 1.0 ± 0.2 0.692–1.308 1.0 ± 0.2 0.636–1.364
RT
 Yes 7.0 ± 1.6 3.875–10.125 6.0 ± 1.6 2.870–9.130
 No 3.0 ± 0.4 2.202–3.798 3.0 ± 0.4 2.200–3.800
ST
 Yes 3.0 ± 0.5 2.022–3.978 3.0 ± 0.6 1.876–4.124
 No 3.0 ± 0.7 1.710–4.290 3.0 ± 0.7 1.621–4.379
Overall 3.0 ± 0.5 2.078–3.922 3.0 ± 0.5 1.979–4.021
  1. Abbreviations: OS overall survival, CSS cancer-specific survival, N/A means that the median survival time was not available due to death event occurring in fewer than 50% of cases in the cohort, SE standard error, CI confidence interval, RT radiation treatment, ST surgery treatment